论文部分内容阅读
研究对象为46例HIV抗体阳性的重型血友病甲病人,T4+/T8+均低于1.0。病人随机分为4组,每组只接受一种FⅧ制品。第1组用非热处理中纯FⅧ,第2组(11例)用热处理中纯FⅧ。第3组(12组)和第4组(10例)均使用热处理交换FⅧ制品、1、2组FⅧ特异活性分别为0.6和0.9IU/mg蛋白、纤原分别为总蛋白的50%和36%,Fn为1.5%和40%,IgG为10%和6%,IgM为2%和1.3%。3、4组FⅧ的特异活性分别为2和3.6IU/mg蛋白,Fn为2%和17%,IgM为2.4%和3%,3组FⅧ中纤原为80%,IgG为4%,而4组FⅧ中纤原和IgG几乎没有。第2、3组FⅧ分别经60℃72小时和60℃
The subjects were 46 cases of HIV-positive severe hemophilia A patients, T4 + / T8 + were less than 1.0. Patients were randomly divided into 4 groups, each receiving only one F VIII products. The first group with non-heat treatment pure F Ⅷ, the second group (11 cases) with heat treatment pure F Ⅷ. Group 3 (group 12) and group 4 (group 10) were treated with heat treatment to exchange F VIII products. The specific activities of FⅧ in group 1 and 2 were 0.6 and 0.9 IU / mg protein, respectively. The fibrinogen was 50% and 36 %, Fn 1.5% and 40%, IgG 10% and 6%, IgM 2% and 1.3%. The specific activities of FⅧ in groups 3 and 4 were 2 and 3.6 IU / mg protein, respectively, with 2% and 17% Fn, 2.4% and 3% IgM, fibrinogen 80% and IgG 4% Group F fibrinogen and IgG almost no. Groups 2 and 3 F Ⅷ were respectively 60 ° C for 72 hours and 60 ° C